semaglutide oral liquid Instructions for Compounded GLP-1 WeightMeds Semaglutide is a once Compounded Semaglutide GLP-1 Care |

Biohacking culture People want to optimize performance and longevity Social media influence Peptides are widely promoted as recovery shortcuts Frustration with slow healing = lack of education by providers on how long tendon/ligament injuries can take to repair Athletes often seek ways to speed recovery beyond natural timelines A Major Concern: Unregulated Products Currently: most peptides are not approved by Health Canada or the FDA manufacturing is largely unregulated quality control is inconsistent This makes it difficult to verify: product purity dosing accuracy contamination risk Current Medical Consensus Peptides show biological promise in preclinical research but lack sufficient human evidence for routine clinical use Important unknowns include: dosing frequency duration long-term safety How Group23 Approaches Regenerative Medicine At Group23 Sports Medicine, we focus on treatments supported by the strongest evidence: structured rehabilitation programs under physiotherapy supervision load management and strength training ideally with strength and conditioning coach platelet-rich plasma (PRP) soft tissue adapted biocompatible hyaluronic acid injections SportVis see www.sportvis.ca high molecular weight cross linked hyaluronic acid injections Monovisc (see www.monovisc.ca), Synolis VA (see www.synolis.com) and Durolane (www.durolane.ca/en/) Blood Flow Restriction (BFR) therapy (see off the shelf and custom bracing strategies These treatments currently have far stronger clinical evidence than experimental peptide therapies

Additionally, Nubo Spa offers exciting monthly specials that we encourage each of our patients to check out

One can use glutathione skin whitening supplements given by doctor or dermatologist

GIP: the potentiator GIP receptor agonism is the second lever in both drugs

GLP-1 receptor agonists also increase intestinal fluid secretion through chloride channel activation, as described in preclinical and clinical motility studies

Phase 2 nearly doubled the dose for little return: 4.5 mg gave 10.8% at 26 weeks against 9.7% for 2.4 mg